US pharma industry decries Brazil’s IP regulation roadblocks
Advocates for the US pharmaceutical industry argue that the lack of regulatory data protections and long patent pendency in the Brazilian intellectual property system are holding them, and Brazil, back. Meanwhile,...To view the full article, register now.
Already a subscriber? Click here to view full article